The Medicines and Healthcare products Regulatory Agency, or MHRA,
said the decision was due to the potential for small particles of
white material to be present in individual vials.
The Mylan recall is being made on behalf of Strides Arcolab
International and relates to Agila-branded supplies, the MHRA added.
The Pennsylvania-based company bought Agila, a unit of India's
Strides Arcolab, for $1.6 billion last year.
(This corrected version of the story fixes the headline and first
paragraph to show drug made in Poland not India)
(Reporting by Ben Hirschler; Editing by David Evans)
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.